Expand JNJ Menu
JNJ MENU

JNJ Latest Press Releases

-- April 21, 2025 --

Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA PRNewswire 9:36 AM

-- April 16, 2025 --

Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference Business Wire 4:28 PM

-- April 15, 2025 --

NYSE Content Advisory: Pre-Market update + Bank of America beats earnings estimates PRNewswire 8:55 AM
Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8% Business Wire 6:25 AM
Johnson & Johnson Reports Q1 2025 Results Business Wire 6:20 AM

-- April 10, 2025 --

Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill PRNewswire 8:05 AM

-- April 8, 2025 --

Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG) PRNewswire 3:00 AM

-- April 7, 2025 --

Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare Conference Business Wire 4:25 PM

-- April 4, 2025 --

TREMFYA (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis PRNewswire 8:05 AM

-- April 2, 2025 --

Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership Business Wire 8:44 AM

-- April 1, 2025 --

Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition Business Wire 4:06 PM
Federal Judge Rejects Johnson & Johnson Bankruptcy Strategy, Paving Way for Talc Victims to Seek Justice in Trial Courts Business Wire 9:29 AM

-- March 31, 2025 --

Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims Business Wire 10:20 PM

-- March 26, 2025 --

RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer PRNewswire 11:45 AM
New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG) PRNewswire 8:03 AM

-- March 25, 2025 --

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan Globe Newswire 1:11 PM

-- March 21, 2025 --

Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years Business Wire 6:00 AM

-- March 20, 2025 --

U.S. FDA approves TREMFYA (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease PRNewswire 6:12 PM
RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025 PRNewswire 8:00 AM

-- March 18, 2025 --

Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjgren's disease, has now received Fast Track designation PRNewswire 8:03 AM

-- March 10, 2025 --

Six Dean Omar Branham Shirley Partners Honored for Representation of Plaintiffs Business Wire 6:05 PM
Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients PRNewswire 8:00 AM

-- March 8, 2025 --

Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis PRNewswire 9:00 AM

-- March 5, 2025 --

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results Business Wire 4:30 PM

-- March 4, 2025 --

Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations Business Wire 4:15 PM

-- February 25, 2025 --

INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI Business Wire 12:54 PM

-- February 21, 2025 --

TREMFYA (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis PRNewswire 7:00 AM

-- February 18, 2025 --

GeminiBio Appoints Mike Stella to Board Business Wire 9:00 AM

-- February 13, 2025 --

New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases PRNewswire 8:05 AM

-- February 11, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ PRNewswire 4:43 PM

-- February 4, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ PRNewswire 3:55 PM

-- February 3, 2025 --

Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference Business Wire 4:30 PM

-- January 28, 2025 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ PRNewswire 12:50 PM

-- January 23, 2025 --

Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology PRNewswire 5:35 AM

-- January 22, 2025 --

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer Globe Newswire 8:30 AM
Johnson & Johnson Reports Q4 and Full-Year 2024 Results Business Wire 6:20 AM

-- January 21, 2025 --

SPRAVATO (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression PRNewswire 8:00 AM

-- January 15, 2025 --

New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer PRNewswire 8:00 AM

-- January 13, 2025 --

INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI Business Wire 6:38 PM
Dean Omar Branham Shirley's Partners Named to List of 500 Leading Lawyers in America Business Wire 1:06 PM
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc. Globe Newswire 6:32 AM
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc. Business Wire 6:30 AM

-- January 9, 2025 --

Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis PRNewswire 8:04 AM

-- January 8, 2025 --

Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease PRNewswire 8:00 AM

-- January 7, 2025 --

RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib PRNewswire 8:00 AM

-- January 2, 2025 --

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025 Business Wire 8:00 AM

-- December 12, 2024 --

Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference Business Wire 4:30 PM

-- December 9, 2024 --

CARVYKTI (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study PRNewswire 7:30 PM
Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options PRNewswire 8:00 AM

-- December 8, 2024 --

DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma PRNewswire 7:30 PM
TECVAYLI (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma PRNewswire 12:33 PM
DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma PRNewswire 11:21 AM

-- December 2, 2024 --

Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA (guselkumab) PRNewswire 8:00 AM

-- November 22, 2024 --

Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor PRNewswire 8:00 AM